Literature DB >> 20336264

[Neuroanaesthesia. Principles of optimized perioperative management].

G Herzer1, H Trimmel.   

Abstract

Because of the high vulnerability of the brain as a primary target, neuroanaesthesia requires a close look at basic physiological principles and factors of influence during surgery and subsequent intensive care. Anticipatory management is crucial for anaesthesia within the scope of neurosurgical interventions: essential components of anaesthesia management must already be prepared before the surgical procedure. Intracranial compliance and pressure determine the patient's fate; accordingly they have to be assessed correctly and measured continuously. Advanced methods of monitoring allow sophisticated and individually focused treatment thus contributing to patient safety. Only few pharmacologic approaches have been proven with solid evidence, yet some new studies have revealed interesting brain protective effects of pharmacological and/or adjuvant therapeutic measures. For the treatment of intracranial hypertension, osmotherapy is still of the highest value. Decompressive craniotomy seems to have become a promising alternative, although this must be judged to date as a last resort therapy. Perioperative care of patients with complex intracranial pathologies thus needs a close interaction and cooperation between the operation theatre and intensive care units in the sense of continuous track anaesthesia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20336264     DOI: 10.1007/s00101-010-1708-8

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  27 in total

1.  Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  M J Glantz; B F Cole; P A Forsyth; L D Recht; P Y Wen; M C Chamberlain; S A Grossman; J G Cairncross
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.

Authors:  Phil Edwards; Miguel Arango; Laura Balica; Rowland Cottingham; Hesham El-Sayed; Barbara Farrell; Janice Fernandes; Tamar Gogichaisvili; Nyoman Golden; Bennie Hartzenberg; Mazhar Husain; Mario Izurieta Ulloa; Zouheir Jerbi; Hussein Khamis; Edward Komolafe; Véronique Laloë; Gabrielle Lomas; Silke Ludwig; Guy Mazairac; Maria de los Angeles Muñoz Sanchéz; Luis Nasi; Fatos Olldashi; Patrick Plunkett; Ian Roberts; Peter Sandercock; Haleema Shakur; Caridad Soler; Reto Stocker; Petr Svoboda; Stefan Trenkler; N K Venkataramana; Jonathan Wasserberg; David Yates; Surakrant Yutthakasemsunt
Journal:  Lancet       Date:  2005 Jun 4-10       Impact factor: 79.321

3.  Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis.

Authors:  Susan L Bratton; Randall M Chestnut; Jamshid Ghajar; Flora F McConnell Hammond; Odette A Harris; Roger Hartl; Geoffrey T Manley; Andrew Nemecek; David W Newell; Guy Rosenthal; Joost Schouten; Lori Shutter; Shelly D Timmons; Jamie S Ullman; Walter Videtta; Jack E Wilberger; David W Wright
Journal:  J Neurotrauma       Date:  2007       Impact factor: 5.269

4.  Guidelines for the management of severe traumatic brain injury. II. Hyperosmolar therapy.

Authors:  Susan L Bratton; Randall M Chestnut; Jamshid Ghajar; Flora F McConnell Hammond; Odette A Harris; Roger Hartl; Geoffrey T Manley; Andrew Nemecek; David W Newell; Guy Rosenthal; Joost Schouten; Lori Shutter; Shelly D Timmons; Jamie S Ullman; Walter Videtta; Jack E Wilberger; David W Wright
Journal:  J Neurotrauma       Date:  2007       Impact factor: 5.269

5.  Clonidine premedication decreases hemodynamic responses to pin head-holder application during craniotomy.

Authors:  T G Costello; J R Cormack
Journal:  Anesth Analg       Date:  1998-05       Impact factor: 5.108

6.  A randomized trial of very early decompressive craniectomy in children with traumatic brain injury and sustained intracranial hypertension.

Authors:  A Taylor; W Butt; J Rosenfeld; F Shann; M Ditchfield; E Lewis; G Klug; D Wallace; R Henning; J Tibballs
Journal:  Childs Nerv Syst       Date:  2001-02       Impact factor: 1.475

Review 7.  Inhalational or intravenous anesthetics for craniotomies? Pro inhalational.

Authors:  Kristin Engelhard; Christian Werner
Journal:  Curr Opin Anaesthesiol       Date:  2006-10       Impact factor: 2.706

8.  Remifentanil vs fentanyl with a target controlled propofol infusion in patients undergoing craniotomy for supratentorial lesions.

Authors:  A Del Gaudio; P Ciritella; F Perrotta; M Puopolo; E Lauta; P Mastronardi; P De Vivo
Journal:  Minerva Anestesiol       Date:  2006-05       Impact factor: 3.051

9.  Oral clonidine pretreatment for haemodynamic stability during craniotomy.

Authors:  R Chadha; V Padmanabhan; A Joseph; K Mohandas
Journal:  Anaesth Intensive Care       Date:  1992-08       Impact factor: 1.669

Review 10.  Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  Bernard S Chang; Daniel H Lowenstein
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

View more
  3 in total

1.  [Anesthesiology: partner or competitor?].

Authors:  C M Körner; M A Weigand; E Martin
Journal:  Chirurg       Date:  2012-04       Impact factor: 0.955

2.  Analgosedation of adult patients with elevated intracranial pressure : Survey of current clinical practice in Austria.

Authors:  Guenther Herzer; Claudia Mirth; Udo M Illievich; Wolfgang G Voelckel; Helmut Trimmel
Journal:  Wien Klin Wochenschr       Date:  2017-07-21       Impact factor: 1.704

3.  Current practice in neurocritical care of patients with subarachnoid haemorrhage and severe traumatic brain injury : Results of the Austrian Neurosurvey Study.

Authors:  Günther Herzer; Udo Illievich; Wolfgang G Voelckel; Helmut Trimmel
Journal:  Wien Klin Wochenschr       Date:  2016-07-12       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.